Baudax Bio Announces Date of Reconvened Annual Meeting of Shareholders
Rhea-AI Summary
Baudax Bio, Inc. (NASDAQ:BXRX) has postponed its 2022 Annual Meeting of Shareholders due to insufficient participation, failing to reach quorum. The meeting will now take place on May 18, 2022, at 9:00 a.m. Eastern Time, and will continue virtually. Shareholders eligible to vote are those registered by the close of business on March 29, 2022. Votes submitted prior will remain valid for the reconvened meeting. The company focuses on innovative pharmaceutical solutions for acute care settings, including its product ANJESO, the first 24-hour IV COX-2 preferential NSAID.
Positive
- Baudax Bio is focused on innovative acute care pharmaceuticals.
- ANJESO is a unique product, being the only 24-hour IV COX-2 preferential NSAID.
Negative
- The Annual Meeting was adjourned due to lack of shareholder participation.
- Failure to reach quorum may indicate low investor engagement or confidence.
News Market Reaction – BXRX
In the trading session that priced this news, BXRX declined 9.72%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Annual Meeting to be reconvened on May 18, 2022
MALVERN, Pa., May 05, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for acute care settings, today announced that it has adjourned its 2022 Annual Meeting of Shareholders (the “Annual Meeting”), without any business being conducted, due to lack of shareholder participation resulting in a failure to reach required quorum. The Annual Meeting will reconvene at 9:00 a.m. Eastern time on May 18, 2022 and will continue to be held virtually at www.virtualshareholdermeeting.com/BXRX2022.
The record date for determining shareholders eligible to vote at the Annual Meeting will remain the close of business on March 29, 2022. Shareholders who have already submitted a proxy do not need to vote again for the reconvened Annual Meeting, as the proxies submitted will remain valid. Shareholders who have already submitted proxies and want to change their vote with respect to Proposals 1 and 2 can update their vote in the manner set forth in the Proxy Statement. Your vote will be recorded at the Annual Meeting in accordance with your most recently submitted proxy.
Shareholders as of close of business on the March 29, 2022 record date who have not voted are encouraged to vote online at www.proxyvote.com or by telephone at 1-800-690-6903. Shareholders needing assistance voting or have questions may contact the Company’s proxy solicitation firm, Kingsdale Advisors, at 1-855-476-6002 or contactus@kingsdaleadvisors.com.
About Baudax Bio
Baudax Bio is a pharmaceutical company focused on innovative products for acute care settings. ANJESO is the first and only 24-hour, intravenous (IV) COX-2 preferential non-steroidal anti-inflammatory (NSAID) for the management of moderate to severe pain. In addition to ANJESO, Baudax Bio has a pipeline of other innovative pharmaceutical assets including two novel neuromuscular blocking agents (NMBs) and a proprietary chemical reversal agent specific to these NMBs. For more information, please visit www.baudaxbio.com.
Forward Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties. Such forward-looking statements reflect Baudax Bio’s expectations about its future performance and opportunities that involve substantial risks and uncertainties. When used herein, the words “anticipate,” “believe,” “estimate,” “may,” “upcoming,” “plan,” “target,” “goal,” “intend,” and “expect,” and similar expressions, as they relate to Baudax Bio or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information available to Baudax Bio as of the date of publication on this internet site, and are subject to a number of risks, uncertainties, and other factors that could cause Baudax Bio’s performance to differ materially from those expressed in, or implied by, these forward-looking statements. These forward-looking statements should be considered together with the risks and uncertainties that may affect Baudax Bio’s business and future results included in Baudax Bio’s filings with the Securities and Exchange Commission at www.sec.gov. These forward-looking statements are based on information currently available to Baudax Bio, and Baudax Bio assumes no obligation to update any forward-looking statements except as required by applicable law.
CONTACT:
Investor Relations Contact:
Argot Partners
Sam Martin / Kaela Ilami
(212) 600-1902
baudaxbio@argotpartners.com
Media Contact:
Argot Partners
David Rosen
(212) 600-1902
david.rosen@argotpartners.com
